A new area of cancer immunotherapy is enhancing therapeutic mAb-mediated CD16 activation of NK cells. CAR-NK cells containing multi-specific molecules made up of relatively stable CD16 and other ...

Researchers at The Wistar Institute's HIV Cure and Viral Diseases Center have successfully identified a new approach using ...

NK cells recognize cell-bound antibodies via CD16A (FcγRIIIA) to mediate antibody-dependent cellular cytotoxicity (ADCC). Potentiating therapeutic mAb-mediated CD16 activation of NK cells is an ...

Human NK cells are a subset of peripheral blood lymphocytes defined by the expression of CD56 or CD16 and the absence of the T-cell receptor CD3. NK cells comprise of 10–15% of the lymphocyte ...

The bispecifics are differentiated through their targeting of NKp46 to engage NK cells, rather than the CD16 and NKG2D receptors targeted by other bispecifics. Importantly, NKp46 expression is ...

Immunotherapy. 2011;3(9):1075-1086. MIP-1β release has also been observed for CD56 neg NK cells from patients with HCV infection. The above results suggest that the aberrant CD56 neg NK subset ...

SAR443579 (also known as IPH6101) is a tri-functional NKp46/CD16-based anti-CD123 NK cell engager – described as a first-in-class therapy – that has now advanced into a phase 2 programme.